Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL7386268 | 0.96 | ALDH1A1 (0.42) | ALDH1A1PLA2G2AMEN1KMT2ACYP3A4 | |
| Bicarbonate SCHEMBL7386267 | 0.96 | ALDH1A1 (0.42) | ALDH1A1PLA2G2AMEN1KMT2ACYP3A4 | |
| Bicarbonate SCHEMBL7386270 | 0.96 | ALDH1A1 (0.42) | ALDH1A1PLA2G2AMEN1KMT2ACYP3A4 | |
| SCHEMBL6200741 | 0.84 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ACYP3A4CYP1A2 | |
| SCHEMBL6442557 | 0.82 | SMN1; SMN2 (0.43) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL6442051 | 0.81 | PTGDR2 (0.46) | ALDH1A1MEN1KMT2APTGDR2SMN1; SMN2 | |
| SCHEMBL6448402 | 0.81 | CTDSP1 (0.37) | ALDH1A1PLA2G2AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6445203 | 0.81 | CSF1R (0.35) | ALDH1A1PLA2G2AKMT2ASMN1; SMN2LMNA | |
| SCHEMBL27492967 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL3580899 | 0.79 | ALDH1A1 (0.38) | ALDH1A1PLA2G2AKMT2ACYP3A4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1229349-C | Pyridine-3-carboxylic acid derivative | PFIZER (US) | 2005-11-30 | — | — | CN | disclosed |
| EP-1371647-B1 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1495169-A | Pyridine-3-carboxylic acid derivative | — | 2004-05-12 | — | — | CN | disclosed |
| EP-1371647-A2 | Pyridine-3-carboxylic acid derivatives and their use as intermediates | PFIZER INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| EP-1073658-B1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6458951-B2 | FOR TREATMENT OF MALE ERECTILE DYSFUNCTION, FEMALE SEXUAL DYSFUNCTION | PFIZER INC | 2002-10-01 | — | — | US | disclosed |
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | BUNNAGE MARK EDWARD (GB) | 2001-11-08 | — | — | US | disclosed |
| US-6251904-B1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PFIZER INC. | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039271-A1 | Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction | PDE5A, PDE3A, PDE3B | ALDH1A1 254/4885PLA2G2A 2997/4885MEN1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.